Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
In furtherance to our intimation to the stock exchanges on March 31, 2021, that the partnership interest of Cadila Healthcare Limited in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) stood revised from 20% to 12.5% entitling 12.5% share of profit/loss and voting rights, we hereby intimate that post admission of 9 new partners on April 30, 2021, in ABCD Technologies LLP, the partnership interest in ABCD Technologies LLP now stands revised at 6.45% entitling 6.45% share of profit/loss and voting rights.
This is for your information and dissemination.
Thanking you,
Yours faithfully,
For, CADILA HEALTHCARE LIMITED
DHAVAL NARENDRA SONI
Digitally signed by
DHAVAL NARENDRA SONI Date: 2021.04.30 20:16:57 +05'30'
Cadila Healthcare Limited published this content on 01 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 May 2021 07:02:02 UTC.
Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.